Company Profile: Unity Biotechnology, Inc.

Background

Unity Biotechnology, Inc., founded in 2009 and headquartered in South San Francisco, California, is a biotechnology company dedicated to developing therapeutics aimed at slowing, halting, or reversing age-related diseases. The company's primary focus is on creating senolytic medicines that selectively eliminate senescent cells—cells that have ceased to divide and contribute to aging and various chronic conditions. By targeting these cells, Unity aims to extend human healthspan and address diseases such as osteoarthritis, eye diseases, and pulmonary conditions.

Key Strategic Focus

Unity's strategic objectives center on:

• Therapeutic Development: Advancing a pipeline of senolytic drugs targeting age-related diseases.

• Ophthalmologic Specialization: Concentrating efforts on eye diseases, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy.

• Innovative Technologies: Utilizing proprietary platforms to develop small molecules and biologics that selectively target senescent cells.

• Market Expansion: Aiming to capture a significant share of the growing market for age-related disease therapeutics.

Financials and Funding

Unity Biotechnology has secured substantial funding to support its research and development initiatives:

• Total Funding Raised: Approximately $290.6 million.

• Notable Funding Rounds:

• Series B (October 2016): Raised $116 million.

• Series C (March 2018): Secured $55 million, led by EcoR1 Capital Fund.

• Initial Public Offering (IPO): Went public on the Nasdaq exchange on May 3, 2018, raising $85 million at a market capitalization of $700 million.

• Intended Utilization: Funds are primarily allocated to advancing clinical trials, expanding research capabilities, and developing the company's therapeutic pipeline.

Pipeline Development

Unity's key pipeline candidates include:

• UBX1325: A lead drug candidate targeting Bcl-xL to eliminate senescent cells in age-related eye diseases. As of October 2023, UBX1325 is in Phase 2 clinical trials for DME. Positive results from Phase 1 were reported in July 2022, and Phase 2 results in April 2023 demonstrated significant improvement in vision through 48 weeks.

• UBX1967: A preclinical product targeting ophthalmologic diseases.

• UBX2048: A Tie2/VEGF bispecific in development for eye diseases.

• UBX2050: A human anti-Tie2 agonist monoclonal antibody for treating eye diseases.

• UBX2089: An α-Klotho hormone drug candidate being researched for multiple neurology indications.

Technological Platform and Innovation

Unity Biotechnology distinguishes itself through:

• Proprietary Senolytic Technologies: Developing small molecules and biologics that selectively target and eliminate senescent cells.

• Scientific Methodologies: Employing advanced assays and machine learning algorithms to identify and validate therapeutic targets.

• AI-Driven Capabilities: Utilizing artificial intelligence to accelerate drug discovery and optimize clinical trial designs.

Leadership Team

• Dr. Anirvan Ghosh, Ph.D.: Chief Executive Officer and Director. Appointed CEO in 2020, Dr. Ghosh brings extensive experience in neuroscience and drug development.

• Dr. Nathaniel E. David, Ph.D.: Co-Founder and Executive Director. A serial entrepreneur with a background in biotechnology innovation.

• Ms. Lynne Marie Sullivan: Chief Financial Officer and Head of Corporate Development. Oversees financial strategy and corporate growth initiatives.

• Mr. Alexander Hieu Nguyen, J.D.: Chief Legal Officer, Head of Operations, and Corporate Secretary. Manages legal affairs and operational strategies.

• Dr. Jan M. van Deursen: Founder. Renowned for his research in cellular senescence.

• Dr. Judith Campisi, Ph.D.: Founder. A leading scientist in the field of aging and senescence.

• Dr. Daohong Zhou, M.D.: Founder. Noted for his contributions to cancer biology and aging research.

• Dr. Przemyslaw Sapieha, Ph.D.: Chief Scientist. Leads scientific research and development efforts.

• Ms. Alicia Tozier, M.B.A.: Chief Strategy Officer. Guides corporate strategy and business development.

Leadership Changes

• December 2020: Co-founder Nathaniel David stepped down as President but remained on the board.

• July 2024: Alicia Tozier appointed as Chief Strategy Officer.

• January 2025: Federico Grossi, M.D., Ph.D., appointed as Chief Medical Officer.

• March 2025: Yehia Hashad, M.D., joined the board of directors and the science committee.

Competitor Profile

Market Insights and Dynamics

The senolytic therapeutics market is experiencing significant growth, with a total addressable market estimated at $12.5 billion. Unity Biotechnology holds approximately 3.2% of this market, reflecting its competitive position in the industry.

Competitor Analysis

Key competitors include:

• Oisin Biotechnologies: Focuses on senolytic therapies with a market capitalization of $45 million and R&D investment of $12.3 million.

• AgeX Therapeutics: Specializes in regenerative medicine, holding a market capitalization of $38 million and R&D investment of $9.7 million.

• Siwa Therapeutics: Targets aging interventions with a market capitalization of $27 million and R&D investment of $6.5 million.

• Alkahest: Develops therapies for neurodegenerative and age-related diseases, leveraging plasma proteome insights.

• Calico Labs: Aims to understand aging biology and develop interventions for age-related diseases.

Strategic Collaborations and Partnerships

Unity has engaged in significant collaborations to bolster its market position and innovation capacity:

• Ascentage Pharma: Partnered to advance the clinical development of senolytic drug candidate UBX1325, with milestone payments reported in July 2021.

Operational Insights

Unity's strategic considerations include:

• Market Positioning: Focusing on ophthalmologic diseases to address unmet medical needs in age-related conditions.

• Competitive Advantages: Leveraging proprietary senolytic technologies and a robust pipeline to differentiate from competitors.

• Financial Performance: As of 2023, reported revenue of $4.2 million and a net loss of $89.6 million, with cash reserves of $215.7 million.

Strategic Opportunities and Future Directions

Unity's strategic roadmap encompasses:

• Advancing Clinical Trials: Progressing UBX1325 through Phase 2 and into Phase 3 trials for DME and other eye diseases.

• Expanding Pipeline: Developing additional senolytic candidates for various age-related conditions.

• Exploring New Markets: Investigating applications of senolytic therapies in neurology and other therapeutic areas.

• Enhancing Partnerships: Seeking collaborations to accelerate research and commercialization efforts.

Contact Information

• Website: unitybiotechnology.com

• Headquarters: South San Francisco, California, United States

Note: This profile is based on information available as of July 1, 2025.